This report describes the development of a long-acting insulin accomplished by the slow release of hormone from an implantable, biodegradable matrix. Rats made diabetic with streptozotocin received a single subcutaneous implant of insulin-albumin microbeads that released biologically active insulin for periods up to 3 wk. The mean fasting blood glucose level for treated animals was 88 mg/dl as compared with 392 mg/dl for untreated diabetic controls. With a mean starting body weight of 187 g, treated animals gained weight reaching a mean weight of 228 g; in contrast, untreated animals lost weight to a mean of 175 g. When insulin-albumin microbeads were periodically implanted and removed, lower blood glucose levels were only associated with the presence of the implants. The microbead implants biodegraded in 4-8 wk, thus obviating the need for surgical removal. These results suggest that a long-acting insulin may be produced by the entrapment of insulin within a biodegradable matrix. DIABE-TES 32:478-481, May 1983. C ommercially available insulins suffer from the disadvantage of having short half-lives in vivo. The effective half-life of insulin has been increased substantially by the use of insulin-containing polymers. 1 -3 A single subcutaneous implant of an insulin-containing polymer (for example, ethylene vinylacetate) provided up to 1 mo of sustained release of insulin in diabetic animals.
C ommercially available insulins suffer from the disadvantage of having short half-lives in vivo. The effective half-life of insulin has been increased substantially by the use of insulin-containing polymers. 1 -3 A single subcutaneous implant of an insulin-containing polymer (for example, ethylene vinylacetate) provided up to 1 mo of sustained release of insulin in diabetic animals. 4 However, such slow-release polymeric systems have to be removed once all of the insulin has been released. There could also be problems with toxicity or lack of biocompatibility of the polymer material used in the fabrication of slow-release systems.
In this report we present results on the development of a long-acting insulin through the slow release of biologically active insulin from a biodegradable protein matrix. A single subcutaneous implant of this insulin, in the form of crosslinked albumin microbeads, lowered the blood glucose levels of diabetic rats for several weeks. After releasing the hormone, the microbeads completely biodegraded, thus obviating the need for surgical removal of the implants.
MATERIALS AND METHODS

Preparation of microbeads.
Insulin crystals (80 mg beef, 23.3 U/mg, Connaught Laboratories Limited, Willowdale, Ontario, Canada) were suspended in 1.6 ml 1.0 mM sodium phosphate buffer, pH 7.5, containing 1% sodium dodecyl sulfate. Bovine serum albumin (320 mg, RIA grade, Sigma Chemical Company, St Louis, Missouri) was then dissolved in the suspension that was kept at 4°C. Cross-linking was initiated by the addition of 0.4 ml of glutaraldehyde (2.5% wt/wt), to give a final concentration of 0.5%. After rapid mixing, the suspension was pipetted into 50 ml of a stirred corn oil and petroleum ether solution (1:4 by volume). The waterin-oil emulsion that formed was stirred at room temperature for 15 min until the cross-linking reaction was complete. The oil phase was decanted, the microbeads were washed three times with petroleum ether, and dried overnight in a fume hood. Two sizes of microbeads were prepared: small microbeads at a high stirring speed and large microbeads at a low stirring speed. The insulin content of the microbeads was calculated indirectly using a mass balance by determining the insulin in the corn oil-petroleum ether and the petroleum ether wash solutions and by knowing the insulin content of the original suspension. To determine the availability of the entrapped insulin the amount of insulin eluting from 150 mg of microbeads into 1 L of phosphate-buffered saline (37°C, 2 mg gentamycin) was measured for 1 wk. The insulin levels in solution were assayed by the double antibody radioimmunoassay (RIA) technique of Hales and Randle 5 with bovine insulin as the standard. Implantation of microbeads. Insulin-albumin microbeads were tested on diabetic rats. Male Wistar rats (Canadian Breeding Laboratories) were rendered diabetic by an intravenous injection of streptozotocin (65 mg/kg body wt). 6 The microbeads were implanted in the animals flanks, by means of a small incision in the skin. Each animal received a total dose of 150 mg of the insulin-albumin microbeads, 75 mg of the small microbeads on the right side, and 75 mg of the large microbeads on the left side.
Blood samples (fasted) were taken two times per week after implantation. The blood samples obtained from the orbital sinus under light ether anesthesia were assayed for insulin using an RIA method and for glucose using a Beckman II glucose analyzer (Beckman Instruments, Fullerton, California). Body weights (fasted) were measured two times per week.
Microbeads and the enveloping tissues were removed from individual animals at approximately 2-wk intervals and the extent of biodegradation of the implants was assessed microscopically.
RESULTS
Insulin content and availability. The two sizes of insulinalbumin microbeads that were prepared ranged from a mean diameter of 200 |xm for the small-size microbeads to a mean diameter of 600 jxm for the large-size microbeads ( Figure  1A and 1B, respectively). Light microscopy revealed insulin crystals embedded in the albumin matrix. The insulin content of the microbeads was determined to be 0.2 mg/mg microbeads.
Analysis of the phosphate-buffered saline solution containing both the small-and large-size insulin-albumin microbeads indicates that 67% of the entrapped insulin was released into the solution over a 1-wk period. Insulin and glucose analysis. The blood-insulin levels of diabetic rats implanted subcutaneously with 150 mg of insulin-albumin microbeads are shown in Figure 2 . After implantation of the microbeads, blood insulin levels gradually increased to a maximum of 75 uXI/ml at 10 days postimplantation, after which time there was a gradual decrease. The blood-insulin levels of the treated diabetic rats remained elevated for more than 2 wk. Diabetic control animals, in contrast, did not display any significant increase in their blood insulin levels.
The blood glucose levels of diabetic rats implanted subcutaneously with the microbeads are shown in Figure 2 . The blood glucose levels fell from 370 mg/dl to 95 mg/dl in less than 72 h and remained stable for 14 days. By day 17 the blood glucose levels had increased to 305 mg/dl. By day 21 all animals were hyperglycemic again. In contrast, all control animals displayed mean blood glucose levels between 380 and 410 mg/dl throughout the experiment.
Periodic implantation and removal of the microbeads.
The implantation of insulin-albumin microbeads lowered the blood glucose levels from 320 to 85 mg/dl ( Figure 3 ). When the microbeads were removed, 9 days after implantation, the blood glucose levels rose from 83 to 370 mg/dl within 24 h. After reimplantation of insulin-albumin microbeads several days later, the blood glucose levels decreased again from 385 to 80 mg/dl. Biodegradation of the microbeads. When the microbeads were recovered from the flanks of some of the animals 90 days after subcutaneous implantation, a fibrous capsule or sheath surrounded the implants. Visual examination of the implantation sites, however, showed healthy tissue with no apparent inflammation. The microbeads recovered 28 days after implantation showed varying degrees of biodegradation. The pellet-like implant or clump, observed at 9 days postimplantation, had disappeared at 28 days. In some cases, examination of the subcutaneous implantation site revealed that the smaller microbeads had completely biodegraded; the tissue looked normal and no microbeads were found. In the case of the larger microbeads, some intact microbeads and microbead fragments were found at 28 days and even at 42 days postimplantation. However, at 56 days postimplantation, all of the microbeads had disappeared. Growth and development. Figure 4 shows the change in body weights in experimental animals implanted with insulinalbumin microbeads. In all cases, animals with implanted microbeads gained weight at a rate of approximately 20 g/ wk. While both treated animals and diabetic controls started with body weights of approximately 187 g at day 0, the mean body weight for the treated animals at day 14 had risen to 228 g. In contrast, untreated diabetic controls lost weight and at the end of the experiment their mean body weight was only 175 g.
The subcutaneous implantation of empty albumin microbeads (i.e., without insulin) in diabetic rats had no effect on the animals' blood insulin levels, blood glucose levels, or body weights.
DISCUSSION
The subcutaneous implantation of a single dose of insulinalbumin microbeads in diabetic animals provided a sustained release of insulin for more than 2 wk as demonstrated by the lowering of blood glucose levels ( Figure 2 ) and the increase in body weights (Figure 4) .
The insulin release rate may be controlled by the size of the microbead and the extent of cross-linking of the matrix. The smaller insulin-albumin microbeads disappeared within 4 wk whereas the larger microbeads took up to 8 wk to completely disappear, suggesting that the smaller the microbeads the higher the insulin release rate. In a previous in vivo study with highly cross-linked insulin-albumin microbeads, up to 2 mo of sustained insulin release was observed, 7 indicating that the release rate may be decreased by increasing the extent of cross-linking of the albumin matrix.
The mechanism of release of bioactive macromolecules (M.W. > 1000) such as insulin, from biodegradable systems, such as cross-linked albumin, is not well understood. The fact that 67% of the entrapped insulin eluted from the albumin microbeads into phosphate-buffered saline within 7 days suggests that insulin diffusion out of the albumin matrix probably occurs in vivo in addition to insulin release caused by proteolytic breakdown of the matrix.
Biodegradable systems offer a significant advantage over nondegradable systems because the polymers are eventually absorbed by the body, obviating the need for surgical removal. 89 However, the potential disadvantages must also be considered; the degradation products may be toxic, immunogenic, or carcinogenic. In the case of the albuminmicrobead system, it has been shown that such a matrix produces no adverse immunologic reactions in rabbits. 10 The matrix material has the additional advantage of being readily available and inexpensive. Human albumin, for example, may be obtained from outdated blood or from the recipient's own blood.
In conclusion, biodegradable systems 711 are a potentially better alternative to nondegradable systems 412 in providing for the slow release of insulin in vivo.
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